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Background: Patients with inflammatory bowel diseases (IBD) frequently have extraintestinal 
manifestations including arthritis, sacroiliitis, and ankylosing spondylitis. While the treatment of 
these rheumatological conditions with traditional non-steroidal anti-inflammatory drugs (NSAIDs) 
has been reported to lead to frequent IBD exacerbation, the safety of cyclooxygenase-2 (COX-2) 
inhibitors (Coxibs) remains unclear. 
Objectives: Our aim is to carry out a meta-analysis to verify if Coxibs, employed to treat 
rheumatological manifestations, are associated with an increased risk of exacerbation of IBD 
compared to placebo.
Study Design and Setting: A MEDLINE, SCOPUS, ISI-Web of Knowledge, and EMBASE search 
of all studies published in English from 1965 to April 15, 2015, was conducted. Articles on the safety 
of Coxibs in patients with IBD were identified using the terms “Coxibs or cyclooxygenase-2 inhibitors 
or COX-2 inhibitors AND inflammatory bowel disease.” 
Methods: The criteria of exclusion of the studies were NSAIDs administration within 2 weeks 
before starting Coxibs. For the “proportion” meta-analysis, the studies had to report the proportion 
of patients that had to discontinue the Coxibs therapy due to an exacerbation of IBD; for the “relative 
risk” meta-analysis, the studies had to be prospective with a comparison between patients taking 
Coxibs and patients taking placebo. Two authors independently reviewed titles and abstracts of 
references retrieved from the literature search and selected potentially relevant studies. Differences 
in opinion were resolved by discussion until consensus was reached. If an agreement failed to be 
reached, a third author was consulted. The quality of each study was assessed on a 5-point scale 
adapted from studies by the Quebec Task Force on Whiplash-Associated disorders and Jadad.
Results: The search identified 72 publications of which 7 studies reported the proportion of 
patients with IBD that had to stop the Coxibs therapy because of a worsening of the activity of IBD. 
The pooled proportion of flare up of IBD in patients that received Coxibs was 14.4% (95% CI: 6.7 – 
24.4%). There was no statistically significant difference between patients that assumed Coxibs and 
those that assumed placebo (total fixed effect relative risk = 0.86, 95% CI: 0.39 – 1.88, P = 0.7).
Limitations: A proportion of patients received maintenance therapy with azathioprine or 
6-mercaptopurine and these co-interventions could have protected against a Coxib-induced flare; 
furthermore, the duration of Coxib assumption in the prospective studies is shorter compared to that 
of the medical practice. Three of the studies included in our meta-analysis had an insufficient quality 
but due to the higher number of recruited patients, the studies with a better quality had a higher 
weight in the final result. Moreover, to assess the relative risk of flare up of IBD only randomized 
controlled trials have been used in the second meta-analysis. 
Conclusions: This meta-analysis showed that Coxibs are safe in most patients with IBD. Controlled 
trials of Coxibs compared with NSAIDs would be useful, at least in patients suffering from rheumatic 
pain refractory to standard treatment. 
Key words: Acute pain, ankylosing spondylitis, arthritis, coxibs, chronic pain, inflammatory bowel 
disease, rheumatic manifestations, sacroiliitis 
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tion (13); valdecoxib was associated with an increased 
risk of cardiovascular adverse events (14) and reports of 
serious skin infections (15); and lumiracoxib was associ-
ated with severe liver injury (16). Presently, celecoxib 
and etoricoxib are the only Coxibs available for medical 
use.
A recent Cochrane review (17) (including only 2 
studies) concluded that the results for disease exacerba-
tion and adverse events induced by  the short-term use 
of celecoxib and etoricoxib versus placebo were uncer-
tain in IBD patients, and thus, no definitive conclusions 
regarding the tolerability and safety of these drugs in 
such context could be drawn. 
We report herein, the first meta-analysis about 7 




The MOOSE reporting guidelines for meta-analyses 
have been followed. 
Articles published in English on the safety of Coxibs 
in patients with IBD (defined by a combination of clini-
cal, radiographic, endoscopic, and histologic criteria) 
were identified through MEDLINE, SCOPUS, ISI-Web 
of Knowledge, and EMBASE searches using the terms 
“Coxibs or cyclooxygenase-2 inhibitors or COX-2 inhibi-
tors AND inflammatory bowel disease.” The final date 
of the search was April 15, 2015. 
Reference lists from published articles were also 
employed. Titles of these publications and their ab-
stracts were scanned in order to eliminate duplicates 
and irrelevant articles.  
The criteria of inclusion of the studies were:
a) original studies;
b) the drugs considered as Coxibs were celecoxib, 
etoricoxib, rofecoxib, parecoxib, valdecoxib, lumi-
racoxib, and meloxicam;
c) exclusion of NSAIDs administration within 2 weeks 
before starting Coxibs;
d) for the “proportion” meta-analysis, the studies had 
to report the proportion of patients that had to 
discontinue the Coxibs therapy due to an exacer-
bation of IBD (using the modified disease activity 
index (18) for patients with Crohn’s disease [CD] 
and using the Mayo score (19) for patients with 
ulcerative colitis [UC]);
e) for the “relative risk” meta-analysis, the studies 
had to be prospective with a comparison between 
Inflammatory bowel diseases (IBD) are chronic heterogeneous disorders of the bowel resulting from multi-factorial environmental precipitants in 
genetically susceptible individuals (1). Patients with 
IBD frequently have rheumatological manifestations 
including IBD-associated arthritis, sacroiliitis, and 
ankylosing spondylitis (2).
Safe therapy for acute and chronic pain of these 
rheumatological manifestations constitutes unmet 
medical needs. The treatment with non-steroidal anti-
inflammatory drugs (NSAIDs) has been reported to lead 
to frequent IBD exacerbations (3,4) and thus, these 
drugs are usually not indicated in these patients and 
are listed among the factors causing the flare of IBD, 
although there are still conflicting data (5). 
The pharmacological scenario has changed over 
the last decade thanks to the development of molecules 
like selective cyclo-oxygenase (COX) enzymes inhibitors, 
with the aim of limiting undesirable effects, which for 
the most part should derive from the inhibition of COX-
1. Two COX enzymes, isoform COX-1 and COX-2, are 
responsible for the conversion of arachidonic acid to 
prostaglandins (6). COX-1 is expressed constitutively in 
most tissues (7), and prostaglandins produced by COX-1 
are thought to play a major role in the maintenance of 
gastrointestinal homeostasis, including gastric cytopro-
tection (8). In the bowel, COX-1 is expressed in crypt ep-
ithelial cells (9). As the epithelial cell migrates towards 
the villus, it differentiates, stops expressing COX-1, and 
loses its ability to proliferate. In contrast to the normal 
bowel, COX-2 are expressed in inflamed bowel tissue 
by epithelial cells, lamina propria mononuclear cells, 
and neural cells of the myenteric plexus, upon stimu-
lation by pro-inflammatory cytokines (9-11). Clinically, 
inhibition of COX-1 causes upper and lower gastroin-
testinal (GI) tract toxicity including gastric ulcers, bowel 
ulcers, bowel strictures, and enteritis. On the contrary, 
inhibition of COX-2 results in clinically beneficial anti-
inflammatory and analgesic effects and significantly 
decreases the incidence of upper GI adverse events such 
as ulceration and bleeding over NSAIDs (12).
Because of their specific inhibition, the selective 
COX-2 inhibitors or Coxibs (i.e. celecoxib, etoricoxib, 
rofecoxib, valdecoxib, lumiracoxib) may be associated 
with a lower risk of exacerbation in patients with IBD, 
but whether these drugs can be used safely in these 
patients is still controversial. Some Coxibs have been as-
sociated with an increased risk of adverse events which 
led to their withdrawal from the market: rofecoxib was 
associated with an increased risk of myocardial infarc-
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patients taking Coxibs and patients taking placebo.
There was no restriction for the study design type 
or the sample size.
Two authors (EP and AG) independently reviewed 
titles and abstracts of references retrieved from the lit-
erature search and selected potentially relevant studies. 
The full-text versions of selected studies were then as-
sessed by the 2 authors to determine whether the inclu-
sion criteria were satisfied. Differences in opinion were 
resolved by discussion until consensus was reached. If an 
agreement failed to be reached, a third author (DGR) 
was consulted.
The quality of each study was assessed on a 5-point 
scale adapted from studies by the Quebec Task Force on 
Whiplash-Associated disorders (20) and Jadad (21) for 
each of the following items: (1) type of study; (2) num-
ber of patients; (3) clarity of the inclusion and exclusion 
criteria; (4) type of statistical analysis performed; and (5) 
eventual adjustment for confounding factors. A score of 
0 (weak study, with definite shortcomings), 1 (acceptable 
quality but some weaknesses), or 2 (high quality, without 
important weaknesses) was applied for each item. The 
maximal total score for a good study was 10 points. Data 
abstraction and an estimate of the quality score were 
performed independently by 4 of the authors (DGR, EP, 
AG, and RP) who compared the results and then reached 
a consensus. Assessment was not blind to names and ori-
gins of the authors of the publications.
Statistical Analysis
When heterogeneity was present the random ef-
fects model was preferred to the fixed effects model. 
Cohran’s Q was used to test the heterogeneity and a P 
value < 0.1 was used as a cut-off for significance (22). 
The results of the different studies, with 95% con-
fidence interval (CI) and the overall effect with 95% 
CI, were illustrated in a forest plot graph; the pooled 
effects have been represented using a diamond.
A Freeman-Tukey transformation was used to cal-
culate the weighted summary “proportion.”
The Mantel-Haenszel method was used for calcu-
lating the weighted pooled “relative risk.”
Statistical analyses were conducted using Med Calc 
version 14.8.1 software.
Results
The MEDLINE search identified 72 publications on 
this subject. In 7 studies, the proportion of patients with 
IBD which had to stop the Coxibs therapy because of a 
worsening of the activity of IBD was reported (Table 1).
Included Studies
1. El Miedany et al (23) A multicenter, double-blind, 
placebo randomized controlled trial. Patients with 
IBD. Rheumatic manifestations included arthritis, 
arthralgia, soft tissue rheumatism. Age range: 18 
– 65 years. Exclusion criteria: pregnancy, current 
smoking or former smoker for less than one year 
duration, patients on antibiotic therapy. Sample 
size: 146 participants (76 cases). Therapy with etori-
coxib for 3 months. Follow up: 3 months. Types of 
bowel-related adverse events: not reported.
2. Sandborn et al (24) A multicenter, double-blind, 
placebo randomized controlled pilot trial. Patients 
with UC in remission. Rheumatic manifestations 
included nonspecific arthritis, arthralgia, or other 
condition amenable to NSAID therapy. Age range: 
Table 1. Studies about proportion of  IBD activity worsening in patients treated with Coxibs.
Study Type of  study Disease Rheumatic manifestations Coxib Quality
El Miedany et 
al (23) 
Double-blind, placebo 
randomized controlled trial IBD
Arthritis, arthralgia, soft tissue 
rheumatism Etoricoxib 60 to 120 mg 6
Sandborn et al 
(24) 
Double-blind, placebo 
randomized controlled trial UC
Nonspecific arthritis, arthralgia, or other 
condition amenable to NSAID therapy Celecoxib 200 mg 8
Biancone et al 
(25) Prospective, open-label IBD Arthralgia Rofecoxib 12.5 mg 5
Matuk et al (26) Retrospective IBD Arthritis, myalgia, arthralgia Celecoxib or Rofecoxib 2
Biancone  et al 
(27) Prospective IBD Arthralgia Rofecoxib 12.5 mg 2
Reinisch et al 
(28) Prospective, open-label IBD Peripheral arthropathies, arthralgia Rofecoxib 12.5 to 25 mg 5
Mahadevan et 
al (29) Retrospective IBD
Arthritis, arthralgia, myalgia, abdominal 
pain
Rofecoxib 12.5 to 50 mg 
or celecoxib 200 to 400 mg 2
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18 – 75 years. Exclusion criteria: endoscopic evi-
dence of active colitis; history of gastroduodenal 
ulcer within one month; received any NSAIDs (in-
cluding aspirin), anti-ulcer medication, or antacids 
within 2 weeks; received corticosteroids within 
one month; needed treatment with antibiotics, 
analgesics (except acetaminophen 4 g/day), or cor-
ticosteroids during the study; or had a known sul-
fonamides allergy and/or hypersensitivity to cyclo-
oxygenase inhibitors. Sample size: 217 participants 
(110 cases). Therapy with 2 weeks of celecoxib. 
Follow up: 14 days. Types of bowel-related adverse 
events: abdominal pain (1%), colitis ulcerative 
(2%), aggravated colitis ulcerative (5%), diarrhea 
(1%), flatulence (2%), frequent bowel movements 
(1%); 11% of patients in both groups experienced 
GI adverse events.
3. Biancone et al (25) A prospective study. Patients 
with clinically inactive IBD. Rheumatic manifesta-
tions included arthralgia. Age range: 18 – 80 years. 
Exclusion criteria: concomitant use of NSAIDs, ac-
tive peptic ulcer, previous use of COX-2 inhibitors. 
Sample size: 75 participants (45 cases). Therapy for 
at least 3 days with rofecoxib. Follow up: 3 months. 
Types of bowel-related adverse events: abdominal 
pain (11%), diarrhea (7%), bloody stools (2%); the 
percentage of IBD patients and controls show-
ing GI symptoms was comparable (22% vs. 20%). 
However, although 9 of the 10 patients showing 
side-effects required drug discontinuation (9/45, 
20%), only one of the 6 controls required rofecoxib 
withdrawal (1/30 = 3%) (P < 0.001).
4. Matuk et al (26) A retrospective study. Patients with 
IBD. Rheumatic manifestations included arthritis, 
arthralgia, soft tissue rheumatism. Age range: not 
reported. Exclusion criteria: none. Sample size: 33 
participants (33 cases). Therapy for at least 3 days 
with celecoxib or rofecoxib therapy. Follow up: 
more than 3 years. Types of bowel-related adverse 
events: abdominal pain (33%), aggravated IBD 
(39%), diarrhea (30%), flatulence (3%), bloody 
stools (27%); no comparison with controls.
5. Biancone et al (27) A prospective study. Patients 
with clinically inactive IBD. Rheumatic manifes-
tations included arthralgia. Age range: 18 – 70 
years. Exclusion criteria: history of peptic ulcer, 
concomitant use of NSAIDs, previous use of COX-2 
inhibitors. Sample size: 28 participants (21 cases). 
Therapy for at least 3 days with rofecoxib therapy. 
Follow up: 2 weeks. Types of bowel-related adverse 
events: abdominal pain (5%), diarrhea (10%), 
bloody stools (5%); no controls referred adverse 
events.
6. Reinisch et al (28) A prospective study. Patients 
with clinically inactive IBD.  Rheumatic manifesta-
tions included arthropathy, arthralgia. Age range: 
18 – 70 years. Exclusion criteria: CD restricted to the 
rectum; ileostomy or colostomy; intestinal resection 
within the past 12 months; complications requiring 
surgery; systemic infection; significant hepatic, re-
nal, or cardiovascular disease; a hemoglobin level 
of less than 105 g/L; pregnant or breast-feeding 
women; patients who, in the investigator’s opinion, 
were unlikely to comply with the protocol. Sample 
size: 32 participants (32 cases). Therapy for at least 
20 days with rofecoxib. Follow up: 20 days. Types 
of bowel-related adverse events: diarrhea (3%), 
bloody stools (3%), nausea (3%), mild epigastric 
pain (3%); no comparison with controls.
7. Mahadevan et al (29) A retrospective study. Pa-
tients with IBD. Rheumatic manifestations included 
arthritis, arthralgia, soft tissue rheumatism. Age 
range: 23 – 66 years. Exclusion criteria: none. 
Sample size: 27 participants (27 cases). Therapy for 
at least one week with celecoxib or rofecoxib. Fol-
low up: 9 months. Types of bowel-related adverse 
events: aggravated IBD (7%), asymptomatic colonic 
ulcers found on surveillance colonoscopy (4%); no 
comparison with controls.
Meta-analysis Results
The pooled proportion of flare up of IBD in patients 
that received Coxibs was 14.4% (95% CI: 6.7 – 24.4%) 
(random effects model was applied because the results 
of the studies had heterogeneity with a P < 0.0001 of 
Cohran’s Q) (Table 2, Fig. 1).
Since the studies are focused on different drugs, 
we analyzed individually the drugs for which more than 
one study is present in literature (Celecoxib [24,26], Ro-
fecoxib [25-28]) (Table 3, Fig. 2, Table 4, Fig. 3).
The pooled proportion of flare up of IBD in pa-
tients that received Celecoxib was 23.7% (95% CI: 2.6 
– 85.4%) (random effects model was applied because 
the results of the studies had heterogeneity with a P < 
0.0001 of Cohran’s Q); the pooled proportion of flare 
up of IBD in patients that received Rofecoxib was 18.8% 
(95% CI: 12.4 – 26.8%) (fixed effects model was applied 
because the results of the studies had no heterogeneity 
with a P = 0.41 of Cohran’s Q). 
In the majority of patients, GI symptoms appeared 
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Table 2. Meta-analysis: proportion of  flare up of  IBD.
Fig. 1. Proportion of  flare up of  IBD in patients that assumed Coxibs 
(forest plot).
Study Sample size Proportion (%) 95% CI
El Miedany et al (23) 2006 76 10 .53 4 .66 to 19 .69
Sandborn et al (24) 2006 110 2 .73 0 .57 to 7 .76
Biancone et al (25) 2004 45 20 .00 9 .58 to 34 .60
Matuk et al (26) 2004 33 39 .39 22 .91 to 57 .86
Biancone et al (27) 2003 21 19 .05 5 .45 to 41 .91
Reinisch et al (28) 2003 32 9 .38 1 .98 to 25 .02
Mahadevan et al (29) 2002 27 7 .41 0 .91 to 24 .29




Significance level P < 0.0001
Table 3. Meta-analysis: proportion of  flare up of  IBD for Celecoxib.
Study Sample size Proportion (%) 95% CI
Sandborn et al (24) 2006 110 2 .73 0 .57 to 7 .77
Matuk et al (26) 2004 12 58 .33 27 .67 to 84 .84
Total (random effects) 122 23 .67 2 .62 to 85 .40
Q 21,83
DF 1
Significance level P < 0.0001
Test for heterogeneity
Fig. 2. Proportion of  flare up of  IBD in patients that assumed Celecoxib 
(forest plot).
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after a few days of treatment (duration of 
treatment prior to disease exacerbation 
ranged from less than one week to 6 weeks, 
for those patients taking rofecoxib, and 3 days 
to 4 weeks for those taking celecoxib) (25) 
and subsided promptly on drug discontinua-
tion; in several cases, however, disease activity 
continued to persist despite discontinuation 
of Coxibs and required medical therapy to 
induce disease remission.
A meta-analysis about the comparison 
between the Coxibs and placebo groups con-
cerning the occurrence of gastrointestinal ad-
verse events that led to premature withdrawal 
has been performed in 2 multicenter, random-
ized, double-blind, placebo-controlled trials 
in patients with IBD and suffering from rheu-
matological manifestations (Table 5, Fig. 4).
There was no statistically significant dif-
ference of flare up of IBD in patients that 
assumed Coxibs from patients that assumed 
placebo (total fixed effect relative risk: 0.86, 
95% CI: 0.39 – 1.88, P = 0.7); there was no 
heterogeneity (Cochran’s Q P = 0.79). All the 
adverse events were reversible.
discussion
The results of this meta-analysis show 
that Coxibs are safe in most patients with IBD, 
especially when compared with the high fre-
quency of intestinal adverse events reported 
by the same patients to previously applied 
NSAIDs (27). The absolute rate of flare up of 
IBD in patients that assumed a whole class of 
Coxibs was quite low (14.4%). 
This is confirmed by the fact that GI adverse events led to 
premature withdrawal with similar frequencies in the Coxibs and 
placebo groups (relative risk of flare up of IBD: 0.86, 95% CI: 
0.39 – 1.88, P = 0.7). 
Importantly, no patient experienced cardiovascular adverse 
events. 
In the majority of patients, GI symptoms appeared after a 
few days of treatment and subsided promptly on drug discon-
tinuation (25).
The IBD patient often does not present with merely the 
IBD. Comorbidities are coupled with the overall presentation 
(extraintestinal manifestations like renal complications, asthma, 
cardiomyopathy, etc.). Risks for prescribing a Coxib that could be 
associated with IBD are listed in Table 6.
The different characteristics of the IBD populations between 
the studies may account for the heterogeneity, including the 
number of tested patients (from 21 [27] to 110 [24]), type and 
extent of IBD, and the disease activity. A possible explanation 
for the higher incidence of disease flare, in some retrospective 
studies, could be due to the underestimation of the IBD patients 
Table 4. Meta-analysis: proportion of  flare up of  IBD for Rofecoxib.
Fig. 3. Proportion of  flare up of  IBD in patients that assumed 
Rofecoxib (forest plot).
Meta-analysis: proportion
Study Sample size Proportion (%) 95% CI
Biancone et al (25) 2004 45 20 .00 9 .58 to 34 .60
Matuk et al (26) 2004 23 26 .09 10 .23 to 48 .41
Biancone et al (27) 2003 21 19 .05 5 .45 to 41 .91
Reinisch et al (28) 2003 32 9 .38 1 .98 to 25 .02




Significance level P = 0.41
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exposed to Coxibs: This could have resulted in an 
artificially high incidence of disease exacerba-
tion as those patients who experienced disease 
flare are more likely to report it. 
While the pooled meta-analysis result ad-
dresses the safety of Coxibs in IBD patients in 
term of disease exacerbation, cardiovascular 
safety aspects should not be neglected. In the 
studies considered, the number of patients was 
too small to characterize the more life-threaten-
ing cardiovascular toxicities. 
The limitations of these studies are that a 
proportion of patients received maintenance 
therapy with azathioprine or 6-mercaptopurine 
and these co-interventions could have protected 
against a Coxib-induced flare; furthermore, the 
duration of Coxib assumption in the prospec-
tive studies is shorter compared to that of the 
medical practice. Three of the studies included 
in our meta-analysis had an insufficient quality 
(26,27,29), but due to the higher number of re-
cruited patients, the studies with a better quality 
(23,24) had a higher weight in the final result. 
Moreover, to assess the relative risk of flare up 
of IBD, only randomized controlled trials have 
been used in the second meta-analysis (23,24). 
The studies are focused on different Coxibs, 
so we performed a subanalysis of each drug 
individually and the proportion of flare up of 
IBD resulted: 23.7% for Celecoxib, 18.8% for 
Rofecoxib (14.4% for the whole class). While the 
result for Rofecoxib seems to be consistent (no 
heterogeneity, P = 0.41), the result for Celecoxib 
has a too big confident interval (2.6 to 85.4% 
of IBD flare); so, with the published data in 
literature, it is impossible to conclude whether 
there is a correlation with one medication hav-
ing more side effects. 
Of the drugs considered as Coxibs (cele-
coxib, etoricoxib, rofecoxib, parecoxib, valde-
coxib, lumiracoxib, and meloxicam), no studies 
were found that met the inclusion criteria for 
parecoxib, valdecoxib, lumiracoxib, and meloxi-
Table 5. Meta-analysis: relative risk of  flare up of  IBD.
Fig. 4. Relative risk of  flare up of  IBD in patients that assumed 
Coxibs (forest plot).
Study Intervention Controls Relative risk 95% CI z P
El Miedany et al (23) 2006 8/76 8/70 0 .92 0 .37 to 2 .32    
Sandborn et al (24)  2006 3/110 4/107 0 .73 0 .17 to 3 .18    
Total (fixed effects) 11/186 12/177 0 .86 0 .39 to 1 .88 -0 .38 0 .70
Table 6. Risks for prescribing a Coxib that could be found in IBD.
Contraindications
Sulfonamides allergy 
Active bleeding peptic ulcer
Asthma 
Hypersensitivity to cyclooxygenase inhibitors
Pregnancy or breastfeeding
Cirrhosis Child C
Creatinine clearance less than 30 ml/min
Congestive heart failure NYHA II-IV
Ischemic heart disease 
cam, so no assertions can be made about these drugs with 
these patients.
The risk of aggravating intestinal symptoms by the ad-
ministration of Coxibs may occur mainly in patients with active 
IBD, as COX-2 is important in mucosal repair mechanisms. In 
the analyzed studies, the percentage of GI adverse events was 
lower in the studies in which treatment with Coxibs was started 
in patients with IBD in remission (range 11% [24] to 22% [25]) 
than in those in which the treatment was started without tak-
ing into account the activity of the IBD (up to 58% [26]).  
Pain Physician: November/December 2015; 18:599-607
606  www.painphysicianjournal.com
RefeRences
1. Abraham C, Cho JH. Inflammato-
ry bowel disease. N Engl J Med 2009; 
361:2066-2078.
2. Greenstein AJ, Janowitz HD, Sachar DB. 
The extra-intestinal complications  of 
Crohn’s disease and ulcerative colitis: 
A study of 700 patients. Medicine (Balti-
more) 1976; 55:401-412.
3. Rampton DS, Sladen GE. Relapse of ul-
cerative proctocolitis during treatment 
with non-steroidal anti-inflammatory 
drugs. Postgrad Med J 1981; 57:297-299.
4. Actis GC, Pellicano R, Fadda M, Rosina 
F. Antibiotics and non-steroidal anti- in-
flammatory drugs in outpatient prac-
tice: indications and unwanted effects in 
a gastroenterological setting. Curr Drug 
Saf 2014; 9:133-137.
5. Bonner GF, Walczak M, Kitchen L, Bay-
ona M. Tolerance of nonsteroidal anti-
inflammatory drugs in patients with in-
flammatory bowel disease. Am J Gastro-
enterol 2000; 95:1946-1948.
6. Vane JR. Inhibition of prostaglandin 
synthesis as a mechanism of action for 
aspirin-like drugs. Nature New Biol 1971; 
231:232-235. 
7. O’Neill GP, Ford-Hutchinson AW. Ex-
pression of mRNA for cycloxygenase-1 
and cycloxygenase-2 in human tissues. 
FEBS Lett 1993; 330:156-160.
8. Flemstrom G. Stimulation of HCO3- 
transport in isolated proximal bullfrog 
duodenum by prostaglandins. Am J 
Physiol 1980; 239:G198-G203.
9. Cohn SM, Schloemann S, Tessner T, 
Seibert K, Stenson WF. Crypt stem cell 
survival in mouse intestinal epithelium 
is regulated by prostaglandins synthe-
sized through cyclooyxgenase-1. J Clin 
Invest 1997; 99:1367-1379.
10. Maier JAM, Hla T, Maciag H. Cyclo-
oxygenase is an immediate-early gene 
induced by interleukin-1 in human 
endothelial cells. J Biol Chem 1990; 
265:1085-1088.
11. Hendel J, Nielsen OH. Expression of cy-
clooxygenase-2 mRNA in active inflam-
matory bowel disease. Am J Gastroenterol 
1997; 92:1170-1173.
12. Bombardier C, Laine L, Reicin A, Shap-
iro D, Burgos-Vargas R, Davis B, Day R, 
Ferraz MB, Hawkey CJ, Hochberg MC, 
Kvien TK, Schnitzer TJ; VIGOR Study 
Group. Comparison of upper gastroin-
testinal toxicity of rofecoxib and naprox-
en in patients with rheumatoid arthritis. 
VIGOR Study Group. N Engl J Med 2000; 
343:1520-1528.
13. Jüni P, Nartey L, Reichenbach S, Ster-
chi R, Dieppe PA, Egger M. Risk of car-
diovascular events and rofecoxib: Cu-
mulative meta-analysis. Lancet 2004; 
364:2021-2029.
14. Furberg CD, Psaty BM, FitzGerald GA. 
Parecoxib, valdecoxib, and cardiovascular 
risk. Circulation 2005; 111:249.
15. Byerly FL, Nelson KC, Granko RP, Mor-
rell DS, Cairns BA. Valdecoxib-associated 
acute generalized exanthematous pustu-
losis. Burns 2005; 31:383-387. 
16. Pillans PI, Ghiculescu RA, Lampe G, Wil-
son R, Wong R, Macdonald GA. Severe 
acute liver injury associated with lumi-
racoxib. J Gastroenterol Hepatol 2012; 
27:1102-1105. 
17. Miao XP, Li JS, Ouyang Q, Hu RW, Zhang 
Y, Li HY. Tolerability of selective cycloox-
ygenase 2 inhibitors used for the treat-
ment of rheumatological manifestations 
of inflammatory bowel disease. Cochrane 
Database Syst Rev 2014; 10:CD007744.
18. Munkholm P, Langholz E, Davidsen M, 
Binder V. Disease activity courses in  a re-
gional cohort of Crohn’s disease patients. 
Scand J Gastroenterol 1995; 30:699- 706.
19. Schroeder KW, Tremaine WJ, Ilstrup DM. 
Coated oral 5-aminosalicylic acid therapy 
for mildly to moderately active ulcerative 
colitis. A randomized study. N Engl J Med 
1987; 317:1625-1629.
20. Spitzer WO, Skovron ML, Salmi LR, Cas-
sidy JD, Duranceau J, Suissa S, Zeiss E. 
Scientific monograph of the Quebec 
Task Force on Whiplash-Associated Dis-
orders: Redefining “whiplash” and its 
management. Spine (Phila Pa 1976) 1995; 
20:1S-73S.
21. Jadad AR, Moore RA, Carroll D, Jen-
kinson C, Reynolds DJ, Gavaghan DJ, 
McQuay HJ. Assessing the quality of 
reports of randomized clinical trials: Is 
blinding necessary? Control Clin Trials 
1996; 17:1-12.
22. Higgins JP, Thompson SG, Deeks JJ, Alt-
man DG. Measuring inconsistency in 
meta-analyses. BMJ 2003; 327:557-560.
23. El Miedany Y, Youssef S, Ahmed I, El 
Gaafary M. The gastrointestinal safety 
and effect on disease activity of etoricox-
ib, a selective cox-2 inhibitor in inflam-
matory bowel diseases. Am J Gastroen-
terol 2006; 101:311-317.
24. Sandborn WJ, Stenson WF, Brynskov 
J, Lorenz RG, Steidle GM, Robbins JL, 
Kent JD, Bloom BJ. Safety of celecoxib in 
patients with ulcerative colitis in remis-
sion: A randomized, placebo-controlled, 
pilot study. Clin Gastroenterol Hepatol 
2006; 4:203-211.
25. Biancone L, Tosti C, Geremia A, Fina 
D, Petruzziello C, Emerenziani S, Pal-
lone F. Rofecoxib and early relapse of 
inflammatory bowel disease: An open-
label trial. Aliment Pharmacol Ther 2004; 
19:755-764.
26. Matuk R, Crawford J, Abreu MT, Targan 
SR, Vasiliauskas EA, Papadakis KA. The 
spectrum of gastrointestinal toxicity and 
effect on disease activity of selective cy-
clooxygenase-2 inhibitors in patients 
with inflammatory bowel disease. In-
flamm Bowel Dis 2004; 10:352-356.
27. Biancone L, Tosti C, De Nigris F, Fantini 
M, Pallone F. Selective cyclooxygenase-2 
conclusions
The limited data available suggest that Coxibs are 
safe in most patients with IBD (no difference in GI ad-
verse events in the Coxibs and placebo groups).
There is a need for careful follow-up of patients 
with inactive IBD during the first few days of treatment 
with Coxibs, due to possible relapse requiring drug 
discontinuation. Furthermore, these drugs should not 
be used in case of active IBD, until their safety in this 
context has been assessed by controlled trials. 
While the results of this meta-analysis provide 
a first step in showing the safety of Coxibs in IBD 
patients, double-blind placebo-controlled trials of 
Coxibs compared to NSAIDs would be useful, at least 
in patients suffering from rheumatic pain refractory 
to paracetamol, a drug well tolerated in this cohort 
(30).
Coxib’s and Inflammatory Bowel Diseases
www.painphysicianjournal.com  607
inhibitors and relapse of inflammatory 
bowel disease. Gastroenterology 2003; 
125:637-638.
28. Reinisch W, Miehsler W, Dejaco C, Har-
rer M, Waldhoer T, Lichtenberger C, 
Vogelsang H. An open-label trial of the 
selective cyclo-oxygenase-2 inhibitor, 
rofecoxib, in inflammatory bowel dis-
ease-associated peripheral arthritis and 
arthralgia. Aliment Pharmacol Ther 2003; 
17:1371-1380.
29. Mahadevan U, Loftus EV Jr, Tremaine 
WJ, Sandborn WJ. Safety of selective cy-
clooxygenase-2 inhibitors in inflamma-
tory bowel disease. Am J Gastroenterol 
2002; 97:910-914.
30. Forrest K, Symmons D, Foster P. System-
atic review: Is ingestion of paracetamol 
or non-steroidal anti-inflammatory 
drugs associated with exacerbations of 
inflammatory bowel disease? Aliment 
Pharmacol Ther 2004; 20:1035-1043.

